The report provides a detailed analysis essential for establishing a recombinant human insulin production plant. It encompasses all critical aspects necessary for recombinant human insulin production, including the cost of recombinant human insulin production, recombinant human insulin plant cost, recombinant human insulin production costs, and the overall recombinant human insulin production plant cost.
Additionally, the study covers specific expenditures associated with setting up and operating a recombinant human insulin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Recombinant Human Insulin is a genetically engineered peptide hormone manufactured on a large scale by recombinant DNA (rDNA) technology for various medicinal purposes. Its primary application involves its usage in controlling blood sugar levels in patients with diabetes via insulin therapy.
It is widely utilized as a key supporting ingredient for growth in various cell culture processes. Moreover, it is also used in improving cell proliferation and promoting the production of therapeutic proteins for several applications. It is often employed in advanced therapies and vaccines. Additionally, it is broadly used in research and drug testing to learn more about insulin functions and glucose metabolism.
The market for recombinant human insulin is majorly driven by its applications in the medical and healthcare industries to regulate blood sugar levels in diabetic patients, which fuels its market growth. Moreover, its employment in advanced therapies further enhances its demand in the medical industry.
Its application in pharmacological studies and biotechnological research remarkably boosts its demand in the biotechnology, genetic engineering, research & development industries. Additionally, several factors influence industrial recombinant human insulin procurement, such as the source and purity, cost and pricing, compliance with pharmaceutical regulations, quality standards, technological advancements, environmental considerations, sustainability practices, distribution (including trading and shipping), logistics, safety standards, etc.
Raw Material for Recombinant Human Insulin Production
According to the Recombinant Human Insulin production plant project report, the major raw material for Recombinant Human Insulin production includes Rhizobium japonicum.
Production Process of Recombinant Human Insulin
The extensive Recombinant Human Insulin production cost report consists of the following industrial production process:
- Production from E.coli Bacteria: This method of producing recombinant human insulin involves inserting the insulin gene and a promoter region of the lac operon on the plasmids of E. coli. Here, E. coli is placed in a mixture containing carbon, nitrogen, and phosphorus, which is essential for its growth during the fermentation process. The fermentation process takes place in a bioreactor, where the parameters can be controlled for maximum cell growth and insulin production.
Recombinant Human Insulin is a clear and colourless, water-soluble solution and consists of 51- amino acids. It appears as a white to off-white crystalline substance in its pure form. The chemical formula of the compound is C257H383N65O77S6 and molecular weight is 5.81 kDa. It was first manufactured in 1983 by an American Biotech company. Moreover, its melting point is 233°C and its density is 1.09 g/cm3.
The molecular structure of human insulin is a combination of two peptide chains (dimer), A-chain and B-chain that are linked together by two disulfide bonds. Its storage temperature is around -20°C. Its trademark name is Humulin.
